From WisPolitics.com/WisBusiness.com …
— State health officials are soliciting feedback on how to spend millions in opioid settlement funds Wisconsin is getting next year, part of the $874 million total coming to the state.
The state Department of Health Services today announced a new survey gathering ideas from the public for how these funds should be used, taking input through Sept. 30. It’s focused on the state’s share of funding from the National Prescription Opiate Litigation settlement for fiscal year 2028, which runs from July 1, 2027, through June 30, 2028.
The survey asks respondents for information about where they live and their age, along with their personal connection to substance abuse in the state.
It then asks respondents to rank a number of broad categories for where settlement funds should go, ranging from overdose prevention and treatment to family services, research and more.
Another question directs respondents to select which populations should be prioritized for investment, offering options such as veterans, communities of color, tribal communities, the homeless and other categories. Yet another asks about which treatment strategies should be funded.
“We will use the feedback from the survey to determine where we need to adapt our response efforts to ensure we can continue to save more lives from the dangers of opioid misuse,” DHS Director of Substance Use Initiatives Michelle Haese said in today’s release.
Wisconsin is expected to get more than $874 million in opioid settlement funds between 2022 and 2038, including $11.6 million next year. DHS says it’s put more than $86 million of this funding into fighting the opioid epidemic since 2023.
The appeal for public input comes amid falling overdoses in the state, according to the agency. Wisconsin had 818 opioid overdose deaths in 2024, down from 1,422 in 2023.
See the release below.
Top Stories
– Salmonella infections climb to 431 cases across multiple states: CDC
– Michigan cyclosporiasis cases rise by 368 in a week to 14,277
– Trump’s pick to lead the FDA faces uphill Senate battle
– How Much of a Cancer Drug Is Too Much? Patients, Researchers Challenge FDA-Approved Dosages
– New CDC director acknowledges agency problems in first large staff meeting
– Moderna and Merck shares soar on mRNA cancer vaccine
Press Releases
